A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Clinical trial NCT06732232 · RECRUITING
Trial details
- NCT number
- NCT06732232
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-12
- Primary completion
- 2027-12-12
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.